IGF2 and breast carcinoma: Notably, DCIS.com cells undergo a ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) transition when xenografted (32), suggesting that targeting IGF-II autocrine signaling may act to contain a wide range of breast cancers in situ.